These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9643779)

  • 21. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 22. Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
    Aouba A; Harroche A; Frenzel L; Torchet MF; Rothschild C; François I; Mamzer-Bruneel MF
    Haemophilia; 2015 Jan; 21(1):27-33. PubMed ID: 25545300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII products in haemophilia A: one size fits all?
    Mannucci PM; Garagiola I
    Thromb Haemost; 2015 May; 113(5):911-4. PubMed ID: 25854290
    [No Abstract]   [Full Text] [Related]  

  • 24. Major bleeding disorders: diagnosis, classification, management and recent developments in haemophilia.
    Bhatnagar N; Hall GW
    Arch Dis Child; 2018 May; 103(5):509-513. PubMed ID: 29175823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creutzfeld-Jacob disease and blood product recalls.
    Colvin R; Dubin C; Haas G
    Common Factor; 1994 Apr; (no 10):23. PubMed ID: 11362357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant factor VIII: an introduction.
    Büchel KH
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-4. PubMed ID: 1908119
    [No Abstract]   [Full Text] [Related]  

  • 27. Haemophilia 2002: emerging risks of treatment.
    Evatt BL; Farrugia A; Shapiro AD; Wilde JT
    Haemophilia; 2002 May; 8(3):221-9. PubMed ID: 12010415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant factor VIII: are we really getting more for less?
    Gorlin JB; Ewenstein BM
    J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 31. Acquired immunodeficiency in haemophilia.
    Lancet; 1983 Apr; 1(8327):745. PubMed ID: 6132090
    [No Abstract]   [Full Text] [Related]  

  • 32. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
    Kunst VA; Nováková IR; Haanen C
    Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689
    [No Abstract]   [Full Text] [Related]  

  • 34. [Recombinant factor VIII concentrate].
    Fukutake K
    Rinsho Byori; 1992 Mar; Suppl 92():94-106. PubMed ID: 1583781
    [No Abstract]   [Full Text] [Related]  

  • 35. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
    Kessler CM; Iorio A
    Haemophilia; 2013 May; 19(3):351-4. PubMed ID: 23577743
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibitors in haemophilia: clinical aspects.
    Dimichele D; Rivard G; Hay C; Antunes S
    Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemophilia.
    Aledort LM
    N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.
    White GC; McMillan CW; Kingdon HS; Shoemaker CB
    N Engl J Med; 1989 Jan; 320(3):166-70. PubMed ID: 2492083
    [No Abstract]   [Full Text] [Related]  

  • 39. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 40. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
    N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.